Individual difference in drug metabolism and disposition:: Toxicological significance of genotypes and phenotypes of S-mephenytoin 4′-hydroxylase (CYP2C19)

被引：1

作者：

Ikebuchi, J ^{[1
]}

Yamada, M ^{[1
]}

Ogura, Y ^{[1
]}

Yamamoto, Y ^{[1
]}

Nishimura, A ^{[1
]}

Nishi, K ^{[1
]}

Yamada, K ^{[1
]}

Irizawa, Y ^{[1
]}

机构：

[1] Tottori Univ, Fac Med, Dept Legal Med, Yonago, Tottori 6830826, Japan

来源：

PROGRESS IN FORENSIC GENETICS 9 | 2003年 / 1239卷

关键词：

CYP2C19; genotyping; phenotyping; polymorphism; toxicogenetics;

D O I：

10.1016/S0531-5131(02)00389-8

中图分类号：

Q3 [遗传学];

学科分类号：

071007 ; 090102 ;

摘要：

We examined the relationship between the genetic polymorphism of CYP2C19 and metabolism of omeprazole in order to assess the severity and to predict the outcome of poisoning for forensic and clinical toxicology. The genotypes observed were CYP2C19*1A (wild type), CYP2C19*2 (ml), and CYP2C19*3 (m2). The omeprazole hydroxylation index of the wild-type was -1.15, whereas for the hetero-type it was -0.78, and homo-mutated type 1.22. The genotype of CYP2C19 correlated with the phenotype. The present results proved that genotyping assays of drug metabolizing enzymes are of great value in toxicological significance. (C) 2003 Elsevier Science B.V. All rights reserved.

引用

页码：589 / 592

页数：4

共 50 条

[21] Debrisoquin and S-Mephenytoin hydroxylation phenotypes and CYP2D6 genotypes in an Estonian population
Marandi, T
Dahl, ML
Kiivet, RA
Rago, L
Sjoqvist, F
PHARMACOLOGY & TOXICOLOGY, 1996, 78 (05): : 303 - 307
[22] Enantioselective disposition of rabeprazole in relation to CYP2C19 genotypes
Miura, M
Kagaya, H
Tada, H
Uno, T
Yasui-Furukori, N
Tateishi, T
Suzuki, T
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2006, 61 (03) : 315 - 320
[23] An additional defective allele, CYP2C19*5, contributes to the S-mephenytoin poor metabolizer phenotype in Caucasians
Ibeanu, GC
Blaisdell, J
Ghanayem, BI
Beyeler, C
Benhamou, S
Bouchardy, C
Wilkinson, GR
Dayer, P
Daly, AK
Goldstein, JA
PHARMACOGENETICS, 1998, 8 (02): : 129 - 135
[24] Differences in the incidence of the CYP2C19 polymorphism affecting the S-mephenytoin phenotype in Chinese Han and Bai populations and identification of a new rare CYP2C19 mutant allele
Xiao, ZS
Goldstein, JA
Xie, HG
Blaisdell, J
Wang, W
Jiang, CH
Yan, FX
He, N
Huang, SL
Xu, ZH
Zhou, HH
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 1997, 281 (01): : 604 - 609
[25] Importance of genetic polymorphism of s-mephenytoin-4'-hydroxylase(CYP2C19) in eradication of Helicobacter pylori.
Nisijima, T
Endo, Y
Ota, S
Fujiwara, K
GASTROENTEROLOGY, 2000, 118 (04) : A1284 - A1284
[26] Evaluation of the Effects of 20 Nonsynonymous Single Nucleotide Polymorphisms of CYP2C19 on S-Mephenytoin 4′-Hydroxylation and Omeprazole 5′-Hydroxylation
Wang, Huijuan
An, Nianzhen
Wang, Hao
Gao, Yiwen
Liu, Duan
Bian, Ting
Zhu, Juanli
Chen, Chao
DRUG METABOLISM AND DISPOSITION, 2011, 39 (05) : 830 - 837
[27] A rare variant of human CYP2C19, 2C19:H99I displays altered S-mephenytoin 4′-hydroxylation kinetics
Wester, MR
Yang, M
Richardson, TH
Raucy, JL
Johnson, EF
FASEB JOURNAL, 2000, 14 (08): : A1338 - A1338
[28] Characterization of CYP2C19 and CYP2C9 from human liver:: Respective roles in microsomal tolbutamide, S-mephenytoin, and omeprazole hydroxylations
Lasker, JM
Wester, MR
Aramsombatdee, E
Raucy, JL
ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS, 1998, 353 (01) : 16 - 28
[29] Pharmacodynamic effects and kinetic disposition of rabeprazole in relation to CYP2C19 genotypes
Horai, Y
Kimura, M
Furuie, H
Matsuguma, K
Irie, S
Koga, Y
Nagahama, T
Murakami, M
Matsui, T
Yao, T
Urae, A
Ishizaki, T
ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2001, 15 (06) : 793 - 803
[30] Enantioselective disposition of lansoprazole in relation to CYP2C19 genotypes in the presence of fluvoxamine
Miura, M
Tada, H
Yasui-Furukori, N
Uno, T
Sugawara, K
Tateishi, T
Suzuki, T
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2005, 60 (01) : 61 - 68

← 1 2 3 4 5 →